Kagoshima University
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
3
Ending by 2030
Jun 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 9, 2027The maintenance fee for Antibody gene expression-secretion system (US 10,344,093) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due Apr 15, 2027The maintenance fee for Heterologous polypeptide expression cassette (US 10,443,061) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 3 fees due Jun 15 to 30, 2027 · next Jun 15
- 1 fee due Jul 16, 2027The maintenance fee for Antibody Binding to Cell Adhesion Molecule 3 (US 11,873,337) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
- 2 fees due Aug 13 to 18, 2027 · next Aug 13
- 1 fee due Oct 23, 2027The maintenance fee for Antibody binding to chondroitin sulfate proteoglycan 5 (US 11,965,035) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,021,653 | Shuttle vector for Bifidobacterium and Escherichia coli In force · From the USPTO record | In force | From the USPTO record | |
| US 8,734,779 | 5-fluorouracil-resistant bacteria and method for production thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,911,721 | Method of constructing gene transport support In force · From the USPTO record | In force | From the USPTO record | |
| US 8,951,526 | Antibody against mucin 1 (MUC1) protein and use of same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,738,324 | Growth-regulated viral vector containing the aurora kinase promoter In force · From the USPTO record | In force | From the USPTO record | |
| US 8,902,018 | Method for Controlling Inter-Component Phase Difference Soliton and Inter-Component Phase Difference Soliton Circuit Device In force · High confidence | In force | High confidence | |
| US 10,662,441 | Viral vector targeting cancer stem cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,365,619 | IgG-binding peptide and method for detecting and purifying IgG using same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,212,169 | Benzimidazole Derivative and Use Thereof In force · High confidence | In force | High confidence | |
| US 9,421,122 | Thermotherapy and apparatus for thermotherapy In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 39: 9 patents in force now held by others · 27 lapsed for an unpaid fee · 1 ended at full term · 1 past the fee grace period · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 pending · 15 abandoned · 31 no status recorded